No Big Blockbuster Bailouts Act

This bill changes how the Medicare Drug Price Negotiation Program treats orphan drugs, which are drugs approved only to treat one or more rare diseases or conditions. It removes the current rule that excludes these drugs from negotiation. Instead, an orphan drug could be left out of negotiation only if it falls under a low-Medicare-spending limit, and that limit would be $400 million for orphan drugs instead of the standard $200 million. The changes would apply to drug selection for price years starting on or after January 1, 2028.

Full text and official record on Congress.gov

Sponsors

• Peter Welch Democrat sponsor
• 2 cosponsors